Yuqing Liu

Summary

Affiliation: University of Hong Kong
Country: China

Publications

  1. ncbi Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma
    Yuqing Liu
    Centre for the Study of Liver Disease, Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, China
    Cancer Lett 248:32-40. 2007
  2. ncbi Chemokine receptors support infiltration of lymphocyte subpopulations in human hepatocellular carcinoma
    Yuqing Liu
    Department of Surgery, The University of Hong Kong, Centre for the Study of Liver Disease, L9 57, Faculty of Medicine Building, 21 Sassoon Road, Pokfulam, Hong Kong, China
    Clin Immunol 114:174-82. 2005
  3. ncbi Reduced expression of chemokine receptors on peripheral blood lymphocytes in patients with hepatocellular carcinoma
    Yuqing Liu
    Centre for the Study of Liver Disease and Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, ROC
    Am J Gastroenterol 99:1111-21. 2004
  4. ncbi PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling
    Yuqing Liu
    Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China
    Lab Invest 89:209-21. 2009
  5. ncbi High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis
    Zhen Fan Yang
    Center for the Study of Liver Disease and Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China
    Mol Cancer Ther 5:2261-70. 2006
  6. ncbi Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib
    Yuqing Liu
    Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China
    J Hepatol 55:612-25. 2011
  7. ncbi Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584
    Yuqing Liu
    Centre for the Study of Liver Disease and Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, China
    Cancer Res 65:3691-9. 2005
  8. ncbi Vitamin k epoxide reductase: a protein involved in angiogenesis
    Yibo Wang
    Sino German Laboratory for Molecular Medicine and Hypertension Division, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishilu, Xicheng District, Beijing 100037, P R China
    Mol Cancer Res 3:317-23. 2005
  9. ncbi Effect of physiological heterogeneity of E. coli population on antibiotic susceptivity test
    Yuqing Liu
    Institute of Animal Science and Veterinary Medicine, Shandong Academy of Agricultural Science, Jinan, 250100, China
    Sci China C Life Sci 50:808-13. 2007
  10. ncbi CARP is a novel caspase recruitment domain containing pro-apoptotic protein
    Baohua Liu
    Sino German Laboratory for Molecular Medicine and Center for Molecular Cardiology, Fu Wai Hospital, Chinese Academy of Medical Sciences, 167 Beilishilu, Beijing 100037, China
    Biochem Biophys Res Commun 293:1396-404. 2002

Collaborators

Detail Information

Publications10

  1. ncbi Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma
    Yuqing Liu
    Centre for the Study of Liver Disease, Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, China
    Cancer Lett 248:32-40. 2007
    ..This suggested that blockage of EGF receptors may provide an effective therapeutic approach for human HCC and ANAPD could be a potential drug candidate for the treatment of HCC...
  2. ncbi Chemokine receptors support infiltration of lymphocyte subpopulations in human hepatocellular carcinoma
    Yuqing Liu
    Department of Surgery, The University of Hong Kong, Centre for the Study of Liver Disease, L9 57, Faculty of Medicine Building, 21 Sassoon Road, Pokfulam, Hong Kong, China
    Clin Immunol 114:174-82. 2005
    ..This study demonstrates the role of chemokine receptors in the recruitment of specific lymphocyte subsets to the liver in HCC and suggests the importance of these receptors in regulation of immune defense against HCC...
  3. ncbi Reduced expression of chemokine receptors on peripheral blood lymphocytes in patients with hepatocellular carcinoma
    Yuqing Liu
    Centre for the Study of Liver Disease and Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, ROC
    Am J Gastroenterol 99:1111-21. 2004
    ..The results demonstrated the role of chemokine receptors in recruitment of lymphocytes from peripheral blood to HCC. The findings have important implications in understanding of immunopathogenesis of HCC...
  4. ncbi PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling
    Yuqing Liu
    Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China
    Lab Invest 89:209-21. 2009
    ..These findings provide novel insights into the potential value of blocking VEGF signaling by a small molecule tyrosine kinase inhibitor in treating hepatic fibrosis...
  5. ncbi High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis
    Zhen Fan Yang
    Center for the Study of Liver Disease and Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China
    Mol Cancer Ther 5:2261-70. 2006
    ..In conclusion, PTK787 combined with hypoxia achieved a better therapeutic efficacy than hypoxia alone through enhancing hypoxia-induced antitumor cell effect and preventing the activation of angiogenic process...
  6. ncbi Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib
    Yuqing Liu
    Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China
    J Hepatol 55:612-25. 2011
    ..Nilotinib is a novel tyrosine kinase inhibitor of Bcr-Abl and other kinases. In this study, we have examined its activity as an anti-fibrotic agent...
  7. ncbi Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584
    Yuqing Liu
    Centre for the Study of Liver Disease and Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, China
    Cancer Res 65:3691-9. 2005
    ..Our data suggest that blockage of VEGF receptors may provide an effective therapeutic approach for human hepatocellular carcinoma...
  8. ncbi Vitamin k epoxide reductase: a protein involved in angiogenesis
    Yibo Wang
    Sino German Laboratory for Molecular Medicine and Hypertension Division, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishilu, Xicheng District, Beijing 100037, P R China
    Mol Cancer Res 3:317-23. 2005
    ..Our findings support the impact of VKOR in the process of angiogenesis; hence, the molecule may have a potential application in cardiovascular disease and cancer therapy...
  9. ncbi Effect of physiological heterogeneity of E. coli population on antibiotic susceptivity test
    Yuqing Liu
    Institute of Animal Science and Veterinary Medicine, Shandong Academy of Agricultural Science, Jinan, 250100, China
    Sci China C Life Sci 50:808-13. 2007
    ..However there are few reports concerned with this study. Further research using different kinds of antibiotics with synchronized continuous culture of different bacterial strains is required...
  10. ncbi CARP is a novel caspase recruitment domain containing pro-apoptotic protein
    Baohua Liu
    Sino German Laboratory for Molecular Medicine and Center for Molecular Cardiology, Fu Wai Hospital, Chinese Academy of Medical Sciences, 167 Beilishilu, Beijing 100037, China
    Biochem Biophys Res Commun 293:1396-404. 2002
    ..Our results suggest that CARP is a novel CARD-containing pro-apoptotic protein...